Safety of formoterol turbuhaler used as reliever in asthma: relationship with age and baseline treatment including regular long-acting β2 -agonists (the RELIEF study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002
Addition of formoterol Turbuhaler® to budesonide Turbuhaler® increases the time to first severe exacerbation in long-term treatment of mild asthma: results from OPTIMA Source: Eur Respir J 2001; 18: Suppl. 33, 517s Year: 2001
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) 50mcg over 24 weeks in adults and adolescents with persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Use of step-down design to study dose comparability of budesonide (B) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 534s Year: 2003
Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
LATE-BREAKING ABSTRACT: TRILOGY: a phase III study to evaluate the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) in COPD patients Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 509s Year: 2004
Fluticasone/salmeterol combination (FP/S) for immediate post-exacerbation treatment of childhood asthma Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005
Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS) Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in adults and adolescents with moderate-to-severe persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Ease of use of a two-strip dry powder inhaler (DPI) to deliver fluticasone furoate/vilanterol (FF/VI) and FF alone in asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
LATE-BREAKING ABSTRACT: TRINITY: A phase III study to compare the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) with tiotropium (Tio) and a free triple combination of BDP/FF (Foster®) + Tio in COPD patients Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016
No age effect on systemic exposure to beclometasone and formoterol after pressurized metered dose inhalation in paediatric, adolescent and adult asthma Source: Annual Congress 2013 –Uncontrolled and severe asthma in children Year: 2013
Dose comparability of fluticasone (F) and beclomethasone extrafine aerosol (Q) in children with symptomatic asthma using dose step-down study design Source: Eur Respir J 2003; 22: Suppl. 45, 534s Year: 2003
Efficacy and safety of the new beclomethasone dipropionate/formoterol combination (HFA MDI) vs. budesonide/formoterol (DPI) in moderate to severe persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006
Improved asthma control with budesonide/formoterol via a single inhaler, compared with budesonide alone, in moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: a worldwide, randomised, effectiveness trial (RELIEF Study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002
Healthcare resource use following addition of montelukast to budesonide compared to doubling the dose of budesonide in patients with inadequately controlled asthma (COMPACT trial) Source: Eur Respir J 2004; 24: Suppl. 48, 126s Year: 2004
Pharmacodynamics (PD) of low and high strength budesonide plus formoterol (BF) Spiromax® and BF Turbuhaler® in healthy volunteers (HV) Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013